Literature DB >> 26500963

Virilizing Ovarian Steroid Cell Tumor: A Rare Case.

Aishwarya Bettegowda1, Nagarathnamma Rangaiah2, Nagendra Prasad3, Savitha Channaveeregowda4.   

Abstract

Ovarian steroid cell tumours are fewer than 5 percent of sex-cord stromal tumours and 0.1% of all ovarian tumours. The average age at diagnosis is the mid-20s, but patients can present at virtually any age. We present a case of 38-year-old multipara with history of secondary amenorrhea, clinical signs & symptoms of virilization developed over the past 5 years. With elevated (115ng/dL) serum testosterone level and radiological findings of a left adnexal solid mass; the patient was suspected to have a virilizing tumour of left ovary. Laparoscopic left salpingo-oophorectomy was performed. Histopathology revealed tumour cells in small nests with vacuolated to eosinophilic cytoplasm with nuclear atypia completely replacing the ovarian tissue suggestive of steroid cell tumour (NOS) of ovary. The patient was discharged and advised for follow up with serum testosterone levels after 3 weeks.

Entities:  

Keywords:  Serum testosterone; Sex-cord stromal tumours; Virilizing tumour

Year:  2015        PMID: 26500963      PMCID: PMC4606292          DOI: 10.7860/JCDR/2015/14301.6435

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  1 in total

1.  Ovarian steroid cell tumors (not otherwise specified). A clinicopathological analysis of 63 cases.

Authors:  M C Hayes; R E Scully
Journal:  Am J Surg Pathol       Date:  1987-11       Impact factor: 6.394

  1 in total
  1 in total

1.  Successful laparoscopic resection of virilizing ovarian steroid cell tumor, not otherwise specified, in a 22-year-old woman: a case report and evaluation of the steroidogenic pathway.

Authors:  Jun Matsukawa; Toshifumi Takahashi; Yurika Hada; Wataru Kameda; Kuniaki Ota; Mika Fukase; Kyoko Takahashi; Koki Matsuo; Hideki Mizunuma; Satoru Nagase
Journal:  Fukushima J Med Sci       Date:  2019-12-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.